---
schema_version: "secwatch.filing_event.v1"
accession: "0001404644-24-000089"
form_type: "8-K"
ticker: "NGNE"
cik: "0001404644"
company_name: "Neurogene Inc."
filed_at: "2024-11-04T23:59:59+00:00"
generated_at: "2026-05-30T05:55:01.685903+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Neurogene raises $200M in oversubscribed PIPE; funds into H2 2027

## Summary
- Gross proceeds of ~$200M from sale of 1.835M shares at $50/share and 2.165M pre-funded warrants at $49.999 each.
- Participating investors include RTW Investments, Casdin Capital, EcoR1 Capital, Redmile Group, Great Point Partners, Commodore Capital, Samsara BioCapital.
- Proceeds expected to fund company into second half of 2027 and support NGN-401 registrational study and CMC scale-up.
- Closing expected Nov 5, 2024; post-transaction shares outstanding ~21.0M (assuming full warrant exercise).
- Company to host webcast Nov 11, 2024 to review Phase 1/2 interim data for NGN-401 Rett syndrome gene therapy.

## SEC filing metadata
- accession: 0001404644-24-000089
- form_type: 8-K
- ticker: NGNE
- cik: 0001404644
- company_name: Neurogene Inc.
- filed_at: 2024-11-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1404644/000140464424000089/0001404644-24-000089-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1404644/000140464424000089/ngne-20241104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001404644-24-000089
- JSON: https://secwatch.observer/filing/0001404644-24-000089.json
- Plain text: https://secwatch.observer/filing/0001404644-24-000089.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.